Aranesp coverage decision
Executive Summary
D.C. federal court dismisses Amgen's challenge of the Centers for Medicare & Medicaid Services' decision to reimburse Aranesp (darbepoetin) at the same level as Johnson & Johnson's Procrit (epoetin) under the final Hospital Outpatient Prospective Payment System rule for 2003. In a Dec. 26 1opinion, the court determined that Amgen lacked standing to challenge CMS from implementing certain provisions relating to Aranesp. CMS concluded that the two anemia therapies are "functionally equivalent" (2"The Pink Sheet" Nov. 4, p. 27)...
You may also be interested in...
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.